Journal of
Personalized Medicine

IMPACT FACTOR 3.0
Indexed in: PubMed
CITESCORE 4.1

an Open Access Journal by MDPI

Personalized Medicine in Benign and Malignant Adrenal Tumors

Guest Editors:

Prof. Dr. Massimo Terzolo
Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, 10043 Orbassano, TO, Italy

Dr. Soraya Puglisi
Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, 10043 Orbassano, Turin, Italy

Deadline for manuscript submissions:
closed (15 January 2023)

Message from the Guest Editors

Dear Colleagues,

Adrenocortical carcinoma is a rare endocrine tumor characterized by a grim prognosis, a strong propensity to recur after surgery, and a limited range of available therapeutic options. Therefore, great efforts are required to identify reliable prognostic factors, novel methods to secure early diagnosis and new markers for a timely detection of tumor recurrence following adrenalectomy. Given that the available medical therapies have limited efficacy and are quite toxic, the identification of new molecular targets that can be druggable and the development of innovative therapeutic agents is a definitive priority to improve patient care. In the meanwhile, studies focusing on the efficacy and safety of existing therapies, as well as on quality of life, should be promoted.

This Special Issue will focus on all of these aspects, in particular on genetic, new “omics” markers, differential diagnosis, prognostic factors, as well as therapeutic approaches and their effects. Both original research and review articles are welcome.

Prof. Dr. Massimo Terzolo
Dr. Soraya Puglisi
Guest Editors

Journal of
Personalized Medicine

IMPACT FACTOR 3.0 | Indexed in: PubMed | CITESCORE 4.1

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.
Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
𝕏@JPM_MDPI